• 9 January 2020
    Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited revenue of approximately $10 million for the fourth quarter of 2019 as compared to $0.5 million in the prior year period. For the full year ended December 31, 2019, unaudited revenue was approximately $14 million as compared to $0.7 million for all of 2018. 

    In the United States, revenue for the fourth quarter of 2019 was approximately $8.4 million following the launch of commercial sales of the Axonics r-SNM® System on October 29, 2019, and subsequent FDA approval of urinary clinical indications on November 13, 2019.

    Revenue from international markets totaled approximately $1.6 million in the fourth quarter of 2019 as compared to $0.5 million in revenue in the prior year period. Sales in the fourth quarter of 2019 were derived primarily from r-SNM implants performed in England, the Netherlands, Germany and Switzerland. For all of 2019, international sales from Europe and Canada totaled approximately $5.4 million as compared to sales of $0.7 million in 2018.

    Raymond W. Cohen, CEO of Axonics, commented, “The results of our first sixty days in the U.S. market clearly illustrate the level of enthusiasm for the Axonics r-SNM product and provide evidence that urologists and urogynecologists place a high value on clinical results and innovations that improve patient satisfaction with SNM therapy. We are also satisfied with the results over our first six quarters in select European markets where our customer base and procedure volume continue to grow. Moreover, we believe the market opportunity for sacral neuromodulation consists of millions of patients with overactive bladder and bowel dysfunction that are currently untreated or undertreated. Accordingly, we believe the implant rates and corresponding revenue generated in this category should increase significantly in the years ahead.”

    As of December 31, 2019, subsequent to the follow-on offering completed on November 22, 2019, unaudited cash, cash equivalents and short-term investments were $183.7 million.

    Complete financial results for Q4 2019 and the full year are anticipated to be announced on or about March 4, 2020.